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James C. Moon, MD,a,b,y on behalf of the COVIDsortium InvestigatorsABSTRACTISSOBJECTIVES The purpose of this study was to detect cardiovascular changes after mild severe acute respiratory
syndrome-coronavirus-2 infection.
BACKGROUND Concern exists that mild coronavirus disease 2019 may cause myocardial and vascular disease.
METHODS Participants were recruited from COVIDsortium, a 3-hospital prospective study of 731 health care workers
who underwent first-wave weekly symptom, polymerase chain reaction, and serology assessment over 4 months, with
seroconversion in 21.5% (n ¼ 157). At 6 months post-infection, 74 seropositive and 75 age-, sex-, and ethnicity-matched
seronegative control subjects were recruited for cardiovascular phenotyping (comprehensive phantom-calibrated
cardiovascular magnetic resonance and blood biomarkers). Analysis was blinded, using objective artificial intelligence
analytics where available.
RESULTS A total of 149 subjects (mean age 37 years, range 18 to 63 years, 58% women) were recruited. Seropositive
infections had been mild with case definition, noncase definition, and asymptomatic disease in 45 (61%), 18 (24%), and 11
(15%), respectively, with 1 person hospitalized (for 2 days). Between seropositive and seronegative groups, there were no
differences in cardiac structure (left ventricular volumes, mass, atrial area), function (ejection fraction, global longitudinal
shortening, aortic distensibility), tissue characterization (T1, T2, extracellular volume fraction mapping, late gadolinium
enhancement) or biomarkers (troponin, N-terminal pro–B-type natriuretic peptide). With abnormal defined by the 75
seronegatives (2 SDs from mean, e.g., ejection fraction <54%, septal T1 >1,072 ms, septal T2 >52.4 ms), individuals had
abnormalities including reduced ejection fraction (n ¼ 2, minimum 50%), T1 elevation (n ¼ 6), T2 elevation (n ¼ 9), late
gadolinium enhancement (n ¼ 13, median 1%, max 5% of myocardium), biomarker elevation (borderline troponin
elevation in 4; all N-terminal pro–B-type natriuretic peptide normal). These were distributed equally between seropos-
itive and seronegative individuals.
CONCLUSIONS Cardiovascular abnormalities are no more common in seropositive versus seronegative otherwise
healthy, workforce representative individuals 6 months post–mild severe acute respiratory syndrome-coronavirus-2
infection. (J Am Coll Cardiol Img 2021;14:2155–2166) © 2021 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2021.04.011
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2156T he coronavirus disease-2019 (COVID-19) pandemic caused by severe acuterespiratory syndrome-coronavirus-2
(SARS-CoV-2) has variable clinical impact.
The majority of cases are mild and often
asymptomatic, but a minority of individuals
have severe acute respiratory syndrome, the
most frequent cause of death (1). Multiorgan
involvement occurs in severe disease, and
the cardiovascular system is often involved
in hospitalized COVID-19. Mechanisms
include acute coronary syndrome, exacerba-
tion of pre-existing cardiovascular disease,
arrhythmia, myocarditis, and microangio-
pathic thrombosis (2). Pathophysiological
mechanisms include disordered clotting,superimposed infection, cytokine storm, and hemo-
phagocytic lymphohistiocytosis (3,4). Troponin
elevation is common in severely ill hospitalized pa-
tients (5) and associated with adverse outcomes (6).
However, cardiovascular disease is also a known risk
factor for severe disease (7), so disentangling associa-
tion and causation is challenging.
Cardiovascular magnetic resonance (CMR) has
proven utility for diagnosis in patients with elevated
troponin from unclear causes (8,9) by measuring
cardiac structure, function, myocardial scar (late
gadolinium enhancement), and edema (T1 and T2
mapping). Despite the logistical challenges of CMR
during acute severe hospitalized COVID-19, studies
reported multiple CMR abnormalities in these pa-
tients (10,11).
During convalescence, long-term cardiovascular
effects and their (12) mechanisms are currently un-
clear, but chronic myocarditis has been proposed
following severe hospitalized COVID-19 (13). Recent
CMR studies have reported cardiac abnormalities af-
ter COVID-19 in up to 78% of patients, even afterBarts Heart Centre, Barts Health NHS Trust, West Smithfield, Lo
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ongoing myocardial inflammation in 60% (14). Such a
prevalence of chronic myocarditis after mild disease
has prompted societal concerns in diverse domains
and suggests that screening should be considered
post–COVID-19, even in asymptomatic individuals.
However, study design issues (mixed severe and mild
patients, historic control subjects, CMR sequence
choice, and the definition of normal for mapping),
concern that an isolated elevation of a parameter
such as T1 or T2 is not disease, and errors requiring
post-publication revision (15) have stimulated further
investigation, with particular focus on mild disease.
Furthermore, autopsy studies have suggested that
myocarditis may not be as common as initially
thought (16).
We therefore aimed to determine the prevalence
and extent of late cardiac and cardiovascular sequelae
after mild nonhospitalized SARS-CoV-2 infection.
METHODS
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Substudy, n = 75







Withdrew from study = 2
Left the hospital = 6
CMR contraindication = 5
Seropositive n = 157 Seronegative n = 574





The study design: a nested substudy of the parent COVIDsortium Bioresource.
Ab ¼ antibody; CMR ¼ cardiac magnetic resonance; PCR ¼ polymerase chain reaction.
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2157rheumatological disease, 1% cancer). A total of 38%
were non-White, including 6% of Black ethnicity).
Across the overall study, 21% (n ¼ 157) seroconverted.
Disease was mild in 99%, with 25% asymptomatic and
only 2 hospitalized (2 days, no deaths). All infections
occurred prior to May 1, 2020 (no new seroconver-
sions, no new PCR-positive tests), with more than
90% of infections understood (from PCR, symptoms,
and antibody data) to have been between March 1,
2020, and April 14, 2020 (18,19).
PARTICIPANTS. Participants were invited to the car-
diovascular nested substudy. In total, 74 seropositive
participants (47% of total seropositive patients; 51% of
available seropositive patients [2 withdrew, 6 left the
hospital, and 5 had CMR contraindications (2 preg-
nancy, 1 implant, 1 metallic fragment, and 1 prior
contrast reaction)]) were recruited, along with 75 age-,
sex-, and ethnicity-matched control subjects selected
from volunteering seronegative subjects. Control
subjects were recruited blinded to clinical data.
STUDY PROTOCOL. Blood was taken for cardiac bio-
markers (high-sensitivity troponin T [hsTnT] and N-
terminal pro–B-type natriuretic peptide [NT-proBNP])
and hematocrit. Peripheral and central blood pres-
sures were recorded as the average of suprasystolic
oscillometric blood pressure measurements acquired
over 10 s at 200 Hz in duplicate after a period of rest
in the semisupine position, as per international
guidelines (Cardioscope II BPþ, Uscom Ltd., Sydney,
Australia).
CARDIAC MAGNETIC RESONANCE. Scans were ac-
quired at 2 sites: Royal Free (1 scanner) or Barts (2
scanners) between September 3, 2020, and November
7, 2020, in accordance with infection control guide-
lines (20) on 1.5-T CMR scanners (Magnetom Aera,
Siemens Healthcare, Erlangen, Germany). Given
pandemic pressures, an adapted 30-min protocol was
used. This comprised anatomic images, long- and
short-axis cines, T1, T2, and extracellular volume
fraction (ECV) mapping (a mid-short axis and 4-
chamber view each) with late gadolinium enhance-
ment and aortic pulse wave velocity. T1 mapping used
a modified Look-Locker inversion recovery sequence
(5s[3s]3s pre-contrast, 4s[1s]3s[1s]2s post-contrast).
The contrast was 0.1 mmol/kg Gadoterate meglu-
mine (gadolinium-DOTA, Dotarem, Guerbet S.A.,
Paris, France). Mapping acquisition/analysis followed
international consensus statements (21,22) with
additional quality assurance steps as indicated in the
Supplemental Appendix.
CMR ANALYSIS. All quantitative analyses were per-
formed blinded to participant status. All scans were
initially clinically reported (J.C.M.) and significantincidental extracardiac/cardiac findings and blood test
abnormalities were committee adjudicated (J.C.M.,
C.M., T.A.T.) with appropriate action as needed
(further testing, clinical review). Left ventricular (LV)
structure and function was analyzed using a clinically
validated artificial intelligence (AI) platform (23). Left
atrial (LA) area and global longitudinal shortening was
analyzed by further validated AI approaches (Supple-
mental Methods) (24). Aortic stiffness, distensibility,
and pulse wave velocity were measured using vali-
dated software (ArtFunþ, Imageens, Paris, France) and
central pulse pressure. A standard operating proced-
ure was developed for T1, T2, ECV, and late gadolinium
enhancement (LGE), with all analyses performed by 2
observers (GJ and RA) using Circle CVI42 version 5.12.1
(Circle Cardiovascular Imaging Inc., Calgary, Alberta,
Canada). Quality assurance procedures included re-
view of motion correction, artifact review, the use of
field maps for potential bias errors, and a blinded
contour review by an independent U.S.-based team for
technical errors (P.K.), and clinical plausibility (E.B.S.).
In brief, endocardial and epicardial contours (10%
offset) were drawn and automatically divided into 6
segments. For LGE, a 3-SD approach was taken. LGE






(n ¼ 75) p Value
Demographics
Age, yrs 37 (31–48) 39 (30–48) 37 (31–47) 0.89
Female 86 (58) 46 (62) 40 (53) 0.28
BSA, m2 1.89  0.22 1.88  0.21 1.90  0.23 0.51
Ethnicity
White 103 (69) 50 (68) 53 (71) 0.68
Black 17 (11) 10 (14) 7 (9) 0.42
Asian 20 (13) 11 (15) 9 (12) 0.61
Mixed race 9 (6) 3 (4) 6 (8) 0.49
Role
Doctor 40 (27) 20 (27) 20 (27) 0.96
Nurse 48 (32) 25 (34) 23 (31) 0.68
Ancillary staff 53 (36) 26 (35) 27 (36) 0.91
Other 8 (5) 3 (4) 5 (7) 0.71
Past medical history
Hypertension 14 (9) 10 (14) 4 (5) 0.09
Hyperlipidemia 7 (5) 4 (5) 3 (4) 0.69
Diabetes mellitus 3 (2) 2 (3) 1 (1) 0.62
Smoker (previous or current) 24 (16) 10 (14) 14 (19) 0.39
Family history of CAD 21 (14) 9 (12) 12 (16) 0.5
Asthma/COPD 18 (12) 13 (17) 5 (7) 0.04
Exercise, h/week 3.5 (2.0–5.0) 3.5 (2.0–5.0) 3 (1.5–6.0) 0.84
Symptoms
Asymptomatic 11 (15)
Noncase definitiona 18 (24)
Case definitiona 45 (61)
Values are median (interquartile range), n (%), or mean  SD. aCase definition—at least one of the following
(fever, cough, shortness of breath, anosmia, ageusia, or dysgeusia).
BSA ¼ body surface area; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease;
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2158of <1% of the myocardium at the right ventricular (RV)
insertion points only was ignored. ECV was derived
using a same-day hematocrit. Magnet quality assur-
ance used the T1MES phantom to ensure no differences
between the 3 magnets and no temporal drift (25,26).
Across the 3 magnets, temperature-corrected T1 and T2
was within 0.33% and 0.95%, respectively, with tem-
poral drift of <1% (Supplemental Methods).
POWER CALCULATION. For information about po-
wer calculations, please see the Supplemental
Methods.
STATISTICAL ANALYSIS. Analyses were pre-
specified. The 5 primary analyses were LV ejection
fraction (EF), indexed end-diastolic volume, per-
centage LGE, septal T1, and septal T2. The 5 secondary
analyses were indexed LV mass, indexed LA area,
global longitudinal shortening (average of 3 views),
septal ECV, and aortic distensibility (diaphragm
level). Planned exploratory analyses were global and
segmental mapping, heart rate, NT-proBNP and
hsTnT levels, and blood pressure. Correlations of anySARS-CoV-2–associated cardiovascular abnormalities
were planned with: 1) demographics; 2) immune
response (peak antibody); and 3) symptoms (case
defining, noncase defining, asymptomatic).
Analyses used SPSS Statistics version 26 (IBM,
Armonk, New York). Data were examined for
normality using the Kolmogorov-Smirnov test and
visual inspection of histograms and Q-Q plots. Nor-
mally distributed variables were expressed as mean 
SD; non-normal as median (interquartile range [IQR]).
Proportions were expressed as absolute frequencies
and percentages. Independent and paired Student’s
tests (2-tailed), the Mann-Whitney U test, Wilcoxon
signed-rank test, and chi-square and Fisher exact test
were used as appropriate. The 5 primary and 5 sec-
ondary endpoints were to be considered separately,
with each having a critical 2-sided Benjamini-Hoch-
berg’s p value to be considered significant, assuming
a false discovery rate of 5%.
DATA ACCESS. All individual participant deidenti-
fied data (serology, PCR results, Digital Imaging and
Communications in Medicine images, meta-data, data
dictionaries) are available upon reasonable request
(Supplemental Methods).
RESULTS
PATIENTS. The study CONSORT diagram is shown in
Figure 1. A total of 149 subjects (74 seropositive vs. 75
seronegative; median age 37 years [range 18 to 63
years], 42% men, 32% non-White ethnicity) were
recruited from COVIDsortium and underwent car-
diovascular phenotyping 6 months 9 days (IQR:
5 months 26 days to 6 months 20 days) post–SARS-
CoV-2 infection. Cases were well matched (Table 1).
Seropositive infections had been mild with case
definition symptoms (fever, new dry cough, anosmia,
ageusia, or dysgeusia), noncase definition symptoms,
and asymptomatic disease in 45 (61%), 18 (24%) and 11
(15%) respectively, with 1 person hospitalized (for
2 days). Symptoms had been recorded throughout the
parent study weekly. At the time of scanning
(6 months), 16 (11%) reported symptoms: 5 (3%) sore
throat; 4 (3%) fatigue; 4 (3%) rhinorrhea; 3 (2%)
shortness of breath; and 1 (1%) each of productive
cough, chills, diarrhea, anosmia, and ageusia, with no
difference between seropositive and seronegative
subjects (6 [8%] vs. 10 [13%]; p ¼ 0.47).
STUDY. CMR scanning took a median 30 min (IQR: 27
to 32 min). Example images and the CMR protocol are
shown in Supplemental Figure 1. All data were >99%
complete (see details in the Supplemental Methods).
Segmentation of LV structure, function, LGE, T1, and
T2 are shown in Supplemental Figure 2.
TABLE 2 Primary and Secondary Analyses Results
Whole Cohort (N ¼ 149) Seropositive (n ¼ 74) Seronegative (n ¼ 75) p Value
Blood pressure
Peripheral sBP, mm Hg 119 (109–130) 115 (109–130) 121 (110–131) 0.3
Peripheral dBP, mm Hg 75  9 74  9 75  10 0.58
Laboratory investigations
Hs troponin T (normal <14) 4 (3–7) 4 (3–7) 4 (3–7) 0.57
NT-proBNP (normal <400) 31 (18–54) 36 (18–53) 28 (17–56) 0.24
Function
LVEF, % 67.1 (63.7–70.1) 67.5 (64.4–70.2) 66.8 (62.8–70.1) 0.28*
GLS mean, % 17.4  2.1 17.5  1.8 17.3  2.4 0.62†
Structure
LVEDV indexed, ml/m2 78.8 (70.2–90.9) 78.1 (69.7–90.3) 80.0 (71.3–94.9) 0.37*
LA area indexed, ml/m2 12.0 (10.9–13.1) 12.0 (11.0–13.2) 11.9 (10.6–13.1) 0.87†
LV mass index, g/m2 46.6 (41.2–56.7) 47.5 (41.5–57.6) 47.5 (41.5–56.7) 0.56†
Tissue characterization
LGE, % 0.29  0.86 0.27  0.78 0.32  0.93 0.72*
RV insertion point 14 (9) 8 (11) 6 (8) 0.56
Non-RV insertion point 13 (9) 6 (8) 7 (9) 0.79
T1 septum, ms 1,018  31 1,020  34 1,016  28 0.42*
High 6 (4) 5 (7) 1 (1) 0.12
T1 global, ms 1,009  27 1,010  28 1,007  25 0.47
High 6 (4) 4 (5) 2 (3) 0.44
T2 septum, ms 48.7  2.2 48.8  2.5 48.6  1.9 0.63*
High 9 (6) 7 (9) 2 (3) 0.098
T2 global, ms 48.6  1.9 48.7  1.9 48.4  1.9 0.3
High 7 (5) 4 (5) 3 (4) 0.72
ECV septal, % 22.2  2.1 22.3  2.0 22.1  2.2 0.57†
High 5 (3) 3 (4) 2 (3) 0.68
ECV global, % 21.5  2.0 21.6  1.9 21.5  2.1 0.73
High 4 (3) 3 (4) 1 (1) 0.37
Aortic stiffness
Distensibility, mmHg-1$10-3 12.3 (8.7–17.5) 12.6 (9.1–18.3) 12.0 (8.7–17.1) 0.74†
Values are median (interquartile range), mean  SD, or n (%). NT-proBNP in pg/ml and hs-troponin T in ng/ml. All indexing is to body surface area. *Pre-specified primary
endpoint. †Pre-specified secondary endpoint.
BSA ¼ body surface area; COPD ¼ chronic obstructive pulmonary disease; dBP ¼ diastolic blood pressure; ECV ¼ extracellular volume fraction; EDV ¼ end-diastolic volume;
EF ¼ ejection fraction; GLS ¼ global longitudinal shortening; IQR ¼ interquartile range; LGE ¼ late gadolinium enhancement; LV ¼ left ventricle; LVM ¼ left ventricular mass;
NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; RV ¼ right ventricular; sBP ¼ systolic blood pressure.
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2159PRIMARY AND SECONDARY ENDPOINTS. Between
seropositive and seronegative groups, there were no
statistically significant differences in any of the 5
pre-specified primary endpoints (LVEF, indexed end-
diastolic volume, LGE%, septal T1, septal T2, marked
as dagger in Table 2) or 5 pre-specified secondary end-
points (LV mass indexed, LA area indexed, global lon-
gitudinal shortening [average of 3 views], septal ECV,
and aortic distensibility marked as double daggers in
Table 2), even without correction for multiple testing
(Benjamini-Hochberg’s method), with all p values
>0.05 (Central Illustration). All other comparisonswere
also nonsignificant (Table 2). Between-group differ-
ences between T1 and T2 are shown in Figure 2.
ADDITIONAL ENDPOINTS. There were no between-
group differences (seropositive vs. seronegative)
across any exploratory analyses, including global(rather than septal) T1, T2 or ECV, RV volumes or
RVEF, ascending and descending thoracic aortic pulse
wave velocity, heart rate, NT-proBNP, hsTnT, or
blood pressure. As no CMR or biomarker abnormal-
ities were associated with prior SARS-CoV-2 infection,
further correlations with demographics, immune
response, or symptoms could not be performed.
OTHER CMR ABNORMALITIES. An abnormality was
defined by either departmental standard clinical cut-
points (e.g., aortic root 36 mm), laboratory test normal
ranges (hsTnT <14 ng/l, NT-proBNP <400 pg/l), or for
primary/secondary endpoints, by using the 75 sero-
negative subjects to define abnormal (2 SDs from
mean: e.g., EF <54%, T1 >1,072 ms, T2 >52.4 ms). Mild
abnormalities were found including: aortic root dila-
tation n ¼ 2, all mild), LA dilatation (n ¼ 6, all mild)
reduced LV function (n ¼ 2, EF 50%–53%); T1 elevation


















Phantom-controlled, AI analytics, blinded human oversight
No detectable cardiovascular differences in
5 primary and 5 secondary endpoints
Joy, G. et al. J Am Coll Cardiol Img. 2021;14(11):2155–2166.
Participants were recruited from COVIDsortium, a 3-hospital prospective study of 731 health care workers who underwent first-wave weekly
symptom, polymerase chain reaction, and serology assessment over 4 months, with seroconversion in 21.5% (n ¼ 157). At 6 months post–
mild severe acute respiratory syndrome coronavirus 2 infection, 74 seropositive and 75 age-, sex-, and ethnicity-matched seronegative health
care workers underwent multiparametric cardiac magnetic resonance (CMR). This was phantom controlled, using artificial intelligence
analytics with blinded human oversight. Our main finding was that there were no detectable cardiovascular differences in 5 primary and 5
secondary endpoints.
Joy et al J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 4 , N O . 1 1 , 2 0 2 1
Cardiovascular Impact of Mild COVID-19 N O V E M B E R 2 0 2 1 : 2 1 5 5 – 2 1 6 6
2160(n¼6), T2 elevation (n¼9), non-RV insertion point LGE
(n ¼ 13, median 1%, maximum 5% of myocardium). All
13 cases with positive LGE are shown in Figure 2 (6 were
seropositive, 7 were seronegative: all were noninfarct
pattern, and someof the LGEpatternswere nonspecific
[2 were 3 segments, 1 was 4 segments]). Prevalence of
myocarditis-like scar was 4% both in the seropositive
and seronegative groups (i.e., no significant differ-
ence). There was no pericardial thickening seen in any
subject. Individual participant septal T1 and T2 data in
both groups along with the other primary endpoints
and global T1 andT2 are shown in Figure 3. Note: there is
a single T2 septal outlier (4SD) that is considered on
post hoc review to be erroneously high from poor mo-
tion correction, but has been left in the results. Nosubject had NT-proBNP elevation. A total of 4 subjects
had borderline troponin elevation (maximum26ng/l, 3
seronegative, 1 seropositive). None of these were sta-
tistically more common in the seropositive group.
Clinical results review recommended 2 people to have
notes/full study data review, further imaging (1 echo-
cardiography for aortic valve review, 1 chest radiog-
raphy—both required no further follow-up) and 4
underwent clinical review—2 for reduced LV function,
2 for noninfarct pattern LGE (Figures 2J and 2M
[2M was found to have been chronic and unchanged
since a healthy volunteer study in 2011]).
ABNORMALITY CLUSTERING. Figure 4 shows results
for all 149 subjects (rows) and across the 12 key bio-
markers (10 primary/secondary imaging endpoints








There were 13 subjects with reported LGE outside of the RV insertion point. We show a single slice from all (i.e., no freedom to select cases). In
total, 6 were found in seropositive cases (A to F), and 7 in seronegative cases (G to M). In addition to the low frequency of LGE abnormalities,
the LGE was mainly small-volume, noninfarct pattern and nonspecific. Some may be normal (e.g., a likely septal perforator vessel visible in the
anteroseptum) (A). In 2, the abnormality was 3 segments (M and J). For the rest of these subject results, see Figure 4. For LGE segmentation,
see Supplemental Figure 1. LGE ¼ late gadolinium enhancement; RV ¼ right ventricular.
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2161plus blood biomarkers [columns]). Each horizontal
row (12 across) is a health care worker split by seros-
tatus (right/left) and in age order (top/bottom), for a
total of 1,776 results. A green cell is a normal result;
amber 2SDs abnormal, LGE present or biomarkerabove lab reference range cut-off; red 4 SDs abnormal
or LGE $3 segments; and white is missing data. LGE
subjects are marked with the letters a to m cross-
referencing Figure 3, but only 2 participants (both
seronegative) had LGE that looked clinically


















































There are no statistical differences in any between group comparisons. LGE is not drawn (as 136 were negative with 6 in the seropositive and 7 in the
seronegative; p ¼ NS –making it hard to graph). Septal T1 and T2 were pre-specified endpoints, but global T1 and T2 were also measured and are displayed
here (also with no statistical differences). LGE ¼ late gadolinium enhancement; LVEDVi ¼ left ventricular end-diastolic volume indexed; LVEF ¼ left
ventricular ejection fraction.
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2162significant. A disease phenotype is likely to have
multiple abnormalities cosegregating within individ-
ual patients in a horizontal line, as was found in 1
subject (seronegative subject, age >55 years)
(Figure 4). There were more individual seropositive
participants with isolated values for septal T1 and
septal T2 outside of 2 SDs from the mean than for
seronegative participants, but these differences were
nonsignificant, they did not cosegregate with LGE,
and elevated values were not reproduced with global
rather than septal measurement (Table 2) or with T1
and T2 as a continuous variable (Figure 2).
DISCUSSION
This study demonstrates that in healthy people,
measured cardiovascular abnormalities are common,
but no more common in those who had had mild
SARS-CoV-2 6 months previously compared with
those who had not. In other words, in this population,mild COVID-19 left no measurable cardiovascular
impact on LV structure, function, scar burden, aortic
stiffness, or serum biomarkers. The cardiovascular
phenotyping employed was comprehensive and
measured parameters that reflected cardiac structure
(LV volumes, mass, LA area), function (LVEF, global
longitudinal shortening, mitral annular plane systolic
excursion), inflammation (T1 and T2), focal fibrosis
(LGE), diffuse fibrosis (ECV), aortic compliance, heart
rate, blood pressure, and high-sensitivity troponin
and NT-proBNP.
The study was designed to focus on late effects
after mild (rather than hospitalized) disease,
following an earlier pathfinder study (14) that indi-
cated high (78%) rates of post COVID-19 cardiac
involvement with ongoing myocardial inflammation
in 60%, even after nonhospitalized disease, based on
mapping and late gadolinium enhancement findings.
Subsequent studies have generally been small and
included either convalescent symptomatic patients


























































All 149 subjects ranked by age with the results of the 5 primary and 5 secondary endpoints, plus biomarkers. Each horizontal row (12 across) is a health care
worker, with seropositives (left) and seronegatives (right). A green cell is a normal result, blue is 2 SDs abnormal or LGE present, red is 4 SDs abnormal or
LGE $3 segments, and white is missing data. (A to M) Cross-reference the LGE images in Figure 2. Of the 1,776 results ([12  149] – 12 missing datapoints),
abnormalities cluster in only a few (see the >55-year-old seronegative subject, a horizontal line of 6 abnormal results). Note that when T1 and T2 are
abnormal (15 times), in no case were T1 and T2 abnormal at the same time. There is a single T2 septal outlier (4 SD) considered on post hoc review to be
erroneously from poor motion correction, but has been left in the pre-specified analyses. BNP ¼ B-type natriuretic peptide; ECV ¼ extracellular volume
fraction; EDV ¼ left ventricular end diastolic volume indexed; EF ¼ ejection fraction; GLS ¼ global longitudinal shortening; LAA ¼ left atrial area indexed;
LGE ¼ late gadolinium enhancement; LVM ¼ left ventricular mass index; TNT ¼ troponin T.
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2163(27), post-hospitalized patients (28), or specific pop-
ulations (recovering athletes) (29). These results have
collectively attracted widespread attention, with
mainstream media coverage and downstream societal
impact. Clinicians and experts managing viral
myocarditis patients have queried the atypical dura-
tion of disease and rates of involvement with mild
disease. In line with this, where histology is available
from autopsy, meta-analyses have only occasionally
shown lymphocytic infiltrates suggestive of myocar-
ditis (30,31), but have more commonly found inter-
stitial macrophage infiltration, consistent with otherforms of sepsis. In parallel, there has been discussion
across several stakeholder groups recognizing limi-
tations and differences between the design and
technical methodology and analysis of some studies
(32). Studies have generally included only severe
disease or mixed populations without inclusion of
asymptomatic seroconverters, and have scanned
early following disease or at variable time points,
meaning it is challenging to draw clear conclusions.
Technical limitations include also include the T1
mapping sequence used (high read-out flip angle
rendering it prone to confounding by T2, heart rate,
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2164off resonance, and magnetization transfer) (33) and
the use of historic controls –time, sequence, scanner,
institution, observer, and analysis method affect T1
measurement.
The current study has a number of advantages and
was designed to address the knowledge gaps arising
from prior studies. As a nested substudy of COVID-
sortium, participants were prospectively recruited
predominantly prior to infection, hence minimizing
recruitment bias. This enabled identification of
asymptomatic individuals with the mildest pheno-
type of disease who have not previously been studied
for cardiovascular effects. Bias from symptom recall
was low, and serological testing was comprehensive
due to the parent study design with serial testing at a
median of 10 time points using 2 assays. Control
subjects were recruited from the same study
contemporaneously, and were well matched with
cases. The substudy recruited w50% of seropositive
individuals and matched control subjects. Scanning
of case and control subjects was performed in paral-
lel, and all acquisitions and analysis was performed
blinded to serostatus. Quality control of T1 and T2
measurement was performed via U.S. Food and Drug
Administration– and European Medicines Agency–
approved phantom calibration showing near iden-
tical measurement performance and no temporal drift
during the study. Application of validated AI analytic
tools improves the ability to detect normal (23,24).
New quality assurance methods were used including
field map measurement in a subset and blinded re-
view for region of interest identification by 2 separate
U.S. based teams and review of T1 SD maps to validate
performance (34). All analyses were pre-specified,
and all images and metadata are available on
reasonable request.
STUDY LIMITATIONS. The current study provides
insight only into the short- to medium-term sequelae
of community COVID-19 in workforce representative
subjects age 18 to 69 years with low levels of comor-
bidities, and not the cardiovascular effects post–
severe hospitalized infection or in those with multi-
morbidity. It does not prove that apparently mild
SARS-CoV-2 never causes chronic myocarditis. The
study design would not distinguish between in-
dividuals who had sustained completely healed
myocarditis and pericarditis and those in whom the
heart had never been affected; a cross-sectional
athlete study at 1 month post–mild community
COVID-19 reported a significant pericardial involve-
ment (late enhancement and/or pericardial effusion),
but this study is at 6 months (when the pericardium
was normal). No baseline pre–COVID-19 imaging wasperformed (35). We did not analyze other cardiovas-
cular measures (including exercise testing). It would
not be feasible or appropriate to obtain histological
data from overwise healthy subjects.
CONCLUSIONS
In a workforce representative population, using best-
available study design (prospective recruitment,
contemporaneous control subjects, phantom scanner
calibration, blinded analysis, full data availability to
other researchers), there are no detectable persistent
cardiovascular abnormalities 6 months post–mild
infection with SARS-CoV-2 compared with matched
case control subjects. Thus, screening in asymptom-
atic patients following nonhospitalized COVID-19 is
currently not indicated.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Mild
SARS-CoV-2 infection has not been found to cause
detectable cardiovascular abnormalities 6 months post-
infection in our study.
COMPETENCY IN PATIENT CARE: Our study provides
societal reassurance for the cardiovascular health of
working-age individuals with convalescence from mild
SARS-CoV-2. Screening asymptomatic individuals
following mild diseases is not indicated.
COMPETENCY IN INTERPERSONAL AND
COMMUNICATION SKILLS: It is important to reassure
patients with mild SARS-CoV-2 infection regarding its
cardiovascular effects.
TRANSLATIONAL OUTLOOK: Efforts to understand
cardiovascular injury from SARS-CoV-2 infection require
meticulous attention to study design, including inclusion
of contemporary control groups and measurement quality
control. This study suggests such research should focus
on patients with acute infections or following severe
hospitalized disease, with little benefit from screening
asymptomatic patients following mild community
infection.
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